CN101845017A - Preparation method of atracurium besilate intermediates - Google Patents
Preparation method of atracurium besilate intermediates Download PDFInfo
- Publication number
- CN101845017A CN101845017A CN200910068233A CN200910068233A CN101845017A CN 101845017 A CN101845017 A CN 101845017A CN 200910068233 A CN200910068233 A CN 200910068233A CN 200910068233 A CN200910068233 A CN 200910068233A CN 101845017 A CN101845017 A CN 101845017A
- Authority
- CN
- China
- Prior art keywords
- dimethoxy
- tetrahydroisoquinoline
- bian
- methyl acrylate
- racemize
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a preparation method of atracurium besilate intermediates, comprising the following steps of: reacting tetrahydropapaverine with methyl acrylate or ethyl acrylate in an organic solvent, then reacting the tetrahydropapaverine with pentanediol under alkali catalysis, and finally reacting with oxalic acid addition salts to prepare (1R, 1'R), (1S, 1'S) and (1R, 1'S)-4,10-dioxy-3,11-dioxo tridecylene-1,13-bi-[1-(3,4-dimethoxy benzyl) -6,7-dimethoxy-1,2,3,4- tetrahydroisoquinoline] dioxalate. Because an intermediate 4,10-dioxy-3,11-dioxo-1,12-tridecylene with large synthesis difficulty is avoided in the method, the preparation method has the advantages of simple process, mild condition, high purity of products, high yield, lower cost and convenient industrial production.
Description
Technical field
The present invention relates to a kind of atracurium besilate intermediates preparation, particularly relate to a kind of (1R, 1`R), (1S, 1`S) and (1R, 1`S)-4,10-dioxy-3,11-dioxo tridecylene-1,13-pair-[1-(3,4-dimethoxy Bian Ji)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline] preparation method of dioxalic acid salt.
Background technology
Cisatracurium besylate is a kind of neuromuscular blocking agents with highly selective, non-depolarization type of exploitation after the Phenylsulfonic acid atracurium, it is mainly through non-enzyme decomposition course (Huffman elimination) natural degradation, and decomposes under blood plasma pH value and body temperature and produce active substance.The termination of this blocker neuromuscular effect does not also rely on hepatic and/or renal metabolism, drainage, therefore do not damage influenced action time because of kidney, liver and circulorespiratory system function, be mainly used in the skeletal muscle relaxation when anaesthetizing in the various surgical operations, be convenient to control breathing, and drop into clinical application.(1R, 1`R)-4,10-dioxy-3,11-dioxo tridecylene-1,13-pair-[1-(3,4-dimethoxy Bian Ji)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline] dioxalic acid salt is the key intermediate of synthesizing cis Phenylsulfonic acid atracurium.
Following document: [1] U.S.4,179,507; [2] U.S.5,454,510; [3] WO 92 00965; [4] Eur.J.Med.Chem.16 has all reported (1R in 515,1981,1`R)-4,10-dioxy-3,11-dioxo tridecylene-1,13-pair-[1-(3,4-dimethoxy Bian Ji)-6,7-dimethoxy-1,2,3, the 4-tetrahydroisoquinoline] synthetic method of dioxalic acid salt, following formula is the synthetic route of this compound:
As can be seen from the above equation, relate to compound 4 in the above-mentioned synthetic method as intermediate, 10-dioxy-3,11-dioxo-1,12-13 diene, because the synthetic difficulty of this intermediate is big, therefore synthetic route is longer, the operational condition harshness, and labour intensity is big, post-reaction treatment difficulty, and equipment requirements and raw materials cost height.
Summary of the invention
In order to address the above problem, to the object of the present invention is to provide that technology is simple, mild condition, product purity height, yield height, cost be lower, and be convenient to the atracurium besilate intermediates preparation of suitability for industrialized production.
In order to achieve the above object, atracurium besilate intermediate provided by the invention (chemical name be (1R, 1`R), (1S, 1`S) and (1R, 1`S)-4,10-dioxy-3,11-dioxo tridecylene-1,13-pair-[1-(3,4-dimethoxy Bian Ji)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline] dioxalic acid salt) the preparation method comprise the following step that carries out in order:
1) with racemize, Michael reaction so that take place between the two in R or S tetrahydropapaverine and methyl acrylate or ethyl propenoate in methyl alcohol or alcohol solvent reflux 1.5-3 hour, be cooled to room temperature then, precipitation filters, filtrate is washed with ether, get the white solid racemize, R or S-3-[1-(3,4-dimethoxy Bian Ji)-6,7-dimethoxy-1,2,3, the 4-tetrahydroisoquinoline]-methyl acrylate or ethyl ester;
2) with potassium tert.-butoxide as catalyzer, with above-mentioned racemize, R or S-3-[1-(3,4-dimethoxy Bian Ji)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline]-methyl acrylate or ethyl ester and pentanediol in toluene solvant reflux 2-4 hour, so that carry out transesterify between the two, steam the azeotrope that removes methyl alcohol or ethanol and toluene simultaneously, be cooled to room temperature then, washing, organic phase drying, precipitation gets yellow dope; This dope is dissolved in the proper amount of acetone, drips saturated oxalic acid acetone soln then and do not separate out, filter to there being precipitation again, drying can obtain (1R, 1`R), (1S, 1`S) and (1R, 1`S)-4,10-dioxy-3,11-dioxo tridecylene-1,13-pair-[1-(3,4-dimethoxy Bian Ji)-6,7-dimethoxy-1,2,3, the 4-tetrahydroisoquinoline] dioxalic acid salt, chemical equation is:
Racemize in the described step 1), the mol ratio of R or S tetrahydropapaverine and methyl acrylate or ethyl propenoate is 1: 2.0-4.0.
Described step 2) racemize in, R or S-3-[1-(3,4-dimethoxy Bian Ji)-6,7-dimethoxy-1,2,3, the 4-tetrahydroisoquinoline]-mol ratio of methyl acrylate or ethyl ester and pentanediol is 1.8-2.2: 1, and the mol ratio of potassium tert.-butoxide and pentanediol is 0.08-0.12: 1.
Atracurium besilate intermediates preparation provided by the invention is to make tetrahydropapaverine and methyl acrylate or ethyl propenoate reaction in organic solvent, and then reacts under highly basic catalysis with pentanediol, last and oxalic acid salify and make (1R, 1`R), (1S is 1`S) with (1R, 1`S)-4,10-dioxy-3,11-dioxo tridecylene-1,13-pair-[1-(3,4-dimethoxy Bian Ji)-6,7-dimethoxy-1,2,3, the 4-tetrahydroisoquinoline] dioxalic acid salt.Owing to avoided the big intermediate of synthetic difficulty 4 among this preparation method, 10-dioxy-3,11-dioxo-1,12-13 diene, so technology is simple, mild condition, product purity height, yield height, cost are lower, and are convenient to suitability for industrialized production.
Embodiment
Embodiment 1:
11.5g R-tetrahydropapaverine-N-ethanoyl-L-L-glutamic acid is added the suitable quantity of water dissolving, regulate pH value to 11 with ammoniacal liquor then, the toluene extraction, precipitation adds 5.8g methyl acrylate and 70ml methyl alcohol afterwards, and reflux is 1.5 hours under agitation condition, be cooled to room temperature then, precipitation filters, filtrate is washed with ether, get white solid R-3-[1-(3,4-dimethoxy Bian Ji)-6,7-dimethoxy-1,2,3, the 4-tetrahydroisoquinoline]-methyl acrylate 8.9g;
At above-mentioned 3.5g R-3-[1-(3,4-dimethoxy Bian Ji)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline]-add the 0.43g pentanediol in the methyl acrylate, add 0.05g potassium tert.-butoxide and 100ml toluene then, reflux is 3 hours under agitation condition, steams the azeotrope that removes methyl alcohol and toluene simultaneously, is cooled to room temperature then, washing, the organic phase drying, precipitation gets yellow dope.This dope is dissolved in the proper amount of acetone, drips saturated oxalic acid acetone soln then and do not separate out, filter to there being precipitation again, drying can obtain (1R, 1`R)-4,10-dioxy-3,11-dioxo tridecylene-1,13-pair-[1-(3,4-dimethoxy Bian Ji)-6,7-dimethoxy-1,2,3, the 4-tetrahydroisoquinoline] dioxalic acid salt 3.6g.
Embodiment 2:
12.0g S-tetrahydropapaverine-N-ethanoyl-L-L-glutamic acid is added the suitable quantity of water dissolving, regulate pH value to 11 with ammoniacal liquor then, the toluene extraction; precipitation adds 6.2g ethyl propenoate and 70ml methyl alcohol afterwards, and reflux is 1.5 hours under agitation condition; be cooled to room temperature then, precipitation filters; filtrate is washed with ether, get white solid S-3-[1-(3,4-dimethoxy Bian Ji)-6; 7-dimethoxy-1; 2,3, the 4-tetrahydroisoquinoline]-ethyl propenoate 9.2g.
At above-mentioned 7.2g S-3-[1-(3,4-dimethoxy Bian Ji)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline]-add the 0.88g pentanediol in the ethyl propenoate, add 0.10g potassium tert.-butoxide and 200ml toluene then, reflux is 3 hours under agitation condition, steams the azeotrope that removes ethanol and toluene simultaneously, is cooled to room temperature then, washing, the organic phase drying, precipitation gets yellow dope.This dope is dissolved in the proper amount of acetone, drips saturated oxalic acid acetone soln then and do not separate out, filter to there being precipitation again, drying can obtain (1S, 1`S)-4,10-dioxy-3,11-dioxo tridecylene-1,13-pair-[1-(3,4-dimethoxy Bian Ji)-6,7-dimethoxy-1,2,3, the 4-tetrahydroisoquinoline] dioxalic acid salt 7.1g.
Claims (3)
1. atracurium besilate intermediates preparation, the chemical name of this intermediate be (1R, 1`R), (1S, 1`S) and (1R, 1`S)-4,10-dioxy-3,11-dioxo tridecylene-1,13-pair-[1-(3,4-dimethoxy Bian Ji)-6,7-dimethoxy-1,2,3, the 4-tetrahydroisoquinoline] dioxalic acid salt, it is characterized in that: described preparation method comprises the following step that carries out in order:
1) with racemize, Michael reaction so that take place between the two in R or S tetrahydropapaverine and methyl acrylate or ethyl propenoate in methyl alcohol or alcohol solvent reflux 1.5-3 hour, be cooled to room temperature then, precipitation filters, filtrate is washed with ether, get the white solid racemize, R or S-3-[1-(3,4-dimethoxy Bian Ji)-6,7-dimethoxy-1,2,3, the 4-tetrahydroisoquinoline]-methyl acrylate or ethyl ester;
2) with potassium tert.-butoxide as catalyzer, with above-mentioned racemize, R or S-3-[1-(3,4-dimethoxy Bian Ji)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline]-methyl acrylate or ethyl ester and pentanediol in toluene solvant reflux 2-4 hour, so that carry out transesterify between the two, steam the azeotrope that removes methyl alcohol or ethanol and toluene simultaneously, be cooled to room temperature then, washing, organic phase drying, precipitation gets yellow dope; This dope is dissolved in the proper amount of acetone, drips saturated oxalic acid acetone soln then and do not separate out, filter to there being precipitation again, drying can obtain (1R, 1`R), (1S, 1`S) and (1R, 1`S)-4,10-dioxy-3,11-dioxo tridecylene-1,13-pair-[1-(3,4-dimethoxy Bian Ji)-6,7-dimethoxy-1,2,3, the 4-tetrahydroisoquinoline] dioxalic acid salt, chemical equation is:
2. atracurium besilate intermediates preparation according to claim 1 is characterized in that: racemize in the described step 1), the mol ratio of R or S tetrahydropapaverine and methyl acrylate or ethyl propenoate is 1: 2.0-4.0.
3. atracurium besilate intermediates preparation according to claim 1, it is characterized in that: racemize described step 2), R or S-3-[1-(3,4-dimethoxy Bian Ji)-6,7-dimethoxy-1,2,3, the 4-tetrahydroisoquinoline]-mol ratio of methyl acrylate or ethyl ester and pentanediol is 1.8-2.2: 1, and the mol ratio of potassium tert.-butoxide and pentanediol is 0.08-0.12: 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910068233A CN101845017A (en) | 2009-03-24 | 2009-03-24 | Preparation method of atracurium besilate intermediates |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910068233A CN101845017A (en) | 2009-03-24 | 2009-03-24 | Preparation method of atracurium besilate intermediates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101845017A true CN101845017A (en) | 2010-09-29 |
Family
ID=42769851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910068233A Pending CN101845017A (en) | 2009-03-24 | 2009-03-24 | Preparation method of atracurium besilate intermediates |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101845017A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8293912B2 (en) | 2007-05-01 | 2012-10-23 | Chemagis Ltd. | Process for producing cisatracurium compounds and associated intermediates |
| US8354537B2 (en) | 2007-10-29 | 2013-01-15 | Chemagis Ltd. | R,R1-atracurium salts |
| US8357805B2 (en) | 2007-06-18 | 2013-01-22 | Chemagis Ltd. | (1R,1′R)-atracurium salts separation process |
| US8357807B2 (en) | 2007-05-01 | 2013-01-22 | Chemagis Ltd. | Isoquinolinium compounds useful in the preparation of cisatracurium and associated intermediates |
| US8461338B2 (en) | 2007-03-08 | 2013-06-11 | Chemagis Ltd. | (1R, 1′R)-atracurium salts separation process |
| CN105348148A (en) * | 2015-11-30 | 2016-02-24 | 山东新华制药股份有限公司 | Method for preparing impurity oxalate of intermediate condensation compound of pradaxa |
| CN110724100A (en) * | 2019-11-26 | 2020-01-24 | 山东铂源药业有限公司 | Preparation method of cisatracurium besilate intermediate |
| CN111777554A (en) * | 2019-04-04 | 2020-10-16 | 山东瑞安药业有限公司 | Method for synthesizing cisatracurium besilate |
-
2009
- 2009-03-24 CN CN200910068233A patent/CN101845017A/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8461338B2 (en) | 2007-03-08 | 2013-06-11 | Chemagis Ltd. | (1R, 1′R)-atracurium salts separation process |
| US8293912B2 (en) | 2007-05-01 | 2012-10-23 | Chemagis Ltd. | Process for producing cisatracurium compounds and associated intermediates |
| US8357807B2 (en) | 2007-05-01 | 2013-01-22 | Chemagis Ltd. | Isoquinolinium compounds useful in the preparation of cisatracurium and associated intermediates |
| US8357805B2 (en) | 2007-06-18 | 2013-01-22 | Chemagis Ltd. | (1R,1′R)-atracurium salts separation process |
| US8354537B2 (en) | 2007-10-29 | 2013-01-15 | Chemagis Ltd. | R,R1-atracurium salts |
| CN105348148A (en) * | 2015-11-30 | 2016-02-24 | 山东新华制药股份有限公司 | Method for preparing impurity oxalate of intermediate condensation compound of pradaxa |
| CN105348148B (en) * | 2015-11-30 | 2017-12-26 | 山东新华制药股份有限公司 | The method for preparing the oxalates of the impurity of dabigatran etexilate intermediate condensation product |
| CN111777554A (en) * | 2019-04-04 | 2020-10-16 | 山东瑞安药业有限公司 | Method for synthesizing cisatracurium besilate |
| CN110724100A (en) * | 2019-11-26 | 2020-01-24 | 山东铂源药业有限公司 | Preparation method of cisatracurium besilate intermediate |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101845017A (en) | Preparation method of atracurium besilate intermediates | |
| CN106279074A (en) | A kind of compound and preparation method thereof and the purposes in synthesis Bu Waxitan | |
| CN105348172B (en) | (S) preparation method of the preparation of the mesyl ethamine of 1 (ethyoxyl of 4 methoxyl group 3) phenyl 2 and Apremilast | |
| CN102180823B (en) | A kind of method of refining prolinamide | |
| EP2386544B1 (en) | Preparation of dihydropyridines | |
| CN101316820B (en) | Process for preparation of chiral amlodipine gentisate | |
| CN103265528A (en) | Esomeprazole magnesium preparation method | |
| CN114716375A (en) | Preparation method of tetrahydrobenzyl isoquinoline compound | |
| CN101367746B (en) | Novel method for synthesis of (S)-propisochlor | |
| CN110423219B (en) | Method for resolving tetrahydroisoquinoline compounds | |
| CN101130520A (en) | Novel method for splitting and producing natural (-)-huperzine and non- natural (+)-huperzine by racemate of diastereoisomer salt | |
| CN111039868A (en) | Preparation method of cisatracurium besilate impurity C benzene sulfonate | |
| CN108047032B (en) | By α-ketoglutaric acid to glutaric acid synthetic method | |
| CN103665084A (en) | Method for preparing abiraterone acetate | |
| CN101514163B (en) | Optically pure Sibutramine and process for preparing salt derivative thereof | |
| CN102603595B (en) | Preparation method of (S)-oxiracetam | |
| CN113354581B (en) | Preparation method and application of chiral chloroquine and phosphate thereof | |
| CN104744389A (en) | Method for recycling valsartan methyl ester from valsartan crystallization mother solution | |
| CN102977077A (en) | Method for preparing dabigatran etexilate intermediate | |
| CN104703967A (en) | Method for purifying fluvoxamine free base and method for preparing highly pure fluvoxamine maleate using same | |
| CN108409615B (en) | Method for synthesizing enantiopure tert-butyl sulfenamide | |
| CN109053585B (en) | Synthetic method of triclabendazole | |
| CN102731388B (en) | Method for preparing (R)/(S)-6,6'-dihydroxy-5,5'-biquinoline | |
| CN111777554A (en) | Method for synthesizing cisatracurium besilate | |
| CN109651234A (en) | A kind of synthetic method of Doneppezil Hydrochloride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100929 |